SPECTAcolor viable next generation multinational cancer clinical trial infrastructure
Over 500 patients in and availability of high quality biological materials
SPECTAcolor’s successful start has demonstrated its viability to facilitate next generation cancer clinical trials. Nike Air Max 2017 Heren blauw Nike Air Max 2016 Heren It has been successfully implemented across 21 clinical centers located in nine countries in Europe, has now recruited over 500 patients since its launch in September 2013, and the observed frequency of mutations is similar to that observed in previous colorectal cancer clinical trials. hogan outlet Air Max 2016 Goedkoop In addition, pathological review and core analyses of tumor blocks shipped to the central biobank at Dresden University Hospital for central quality deemed over 98% of the samples were adequate. nike air max 2017 heren zonnebrillen kopen ray ban This successful implementation is evidence that a logistically complex infrastructure to run next generation trials in a multinational setting is feasible.
These results were presented by SPECTAcolor coordinator Dr. Gunnar Folprecht of the Dresden University Hospital at the 2015 Gastrointestinal Cancers Symposium held 15-17 January 2015 in San Francisco.
Treatments for patients with cancer are becoming more and more tailored to the molecular characteristics of the particular patient and disease. Nike air max 90 pas cher max pas cher Consequently, molecularly characterizing a patient’s disease is now a prerequisite for them to access the appropriate clinical trial for their particular cancer. Chaussure Adidas Pas Cher nike air max norge nettbutikk Assessing their tumor, however, is more easily said than done, because the required testing is beyond the scope of most hospitals.